BridgeMD
Tests treatment safety and results for Asthma
Official title Efficacy and Safety Study of 610 in Patients With Severe Asthma
ClinicalTrials.gov ID: NCT06323213
What this study is testing
What is 610?
610 is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for asthma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Able to give written informed consent prior to participation in the study.
- Male or female adults ages 18 to 75 years old when signing the informed consent.
- Documented diagnosis of asthma for at least one year prior to screening.
- History of physician-diagnosed asthma requiring treatment with ICS and at least one other control medication for at least 6 months prior to screening.
You likely can't join if
- Presence of a known pre-existing, clinically important lung condition other than asthma.
- Severe asthma exacerbation within 4 weeks prior to randomization.
- people with any eosinophilic diseases other than asthma.
- Known, pre-existing severe or clinically significant cardiovascular disease.
- known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment.
- people who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.
See the full eligibility criteria
- Able to give written informed consent prior to participation in the study.
- Male or female adults ages 18 to 75 years old when signing the informed consent.
- Documented diagnosis of asthma for at least one year prior to screening.
- History of physician-diagnosed asthma requiring treatment with ICS and at least one other control medication for at least 6 months prior to screening.
- Presence of a known pre-existing, clinically important lung condition other than asthma.
- Severe asthma exacerbation within 4 weeks prior to randomization.
- people with any eosinophilic diseases other than asthma.
- Known, pre-existing severe or clinically significant cardiovascular disease.
- known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment.
- people who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.
- people with allergy/intolerance to a monoclonal antibody.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.